ArticleFrontiers in public health2025
Immunocompromise and early-onset invasive pulmonary aspergillosis in viral pneumonia: a retrospective cohort study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the context of viral pneumonia, immunocompromised status represents a recognized risk factor for invasive pulmonary aspergillosis (IPA), its association with the timing of IPA diagnosis remains unclear. Methods: In the present study, 261 patients hospitalized with viral pneumonia were consecutively enrolled and categorized as immunocompromised hosts (ICHs) or non-ICHs. Baseline characteristics, outcomes, and time to IPA diagnosis were compared. Cox regression was used to evaluate the association between immunocompromised status and adverse outcomes. Patients diagnosed with IPA were further stratified into early (diagnosis within 5 days of admission) and late groups. Logistic regression was employed to evaluate the association of immunocompromised status with early-onset IPA. Results: Among the enrolled patients, 122 (46.7%) were immunocompromised. Relative to the non-ICH group, ICH patients were older, had a lower body mass index, and contained a smaller proportion of never-smokers. They also presented with higher respiratory rates, CRP, PCT, lower PaO₂/FiO₂ ratios, and greater illness severity. Significantly higher rates of invasive mechanical ventilation (20.5% vs. 2.2%), IPA incidence (22.1% vs. 9.4%), and 30-day mortality (23.8% vs. 5.0%) were observed in the ICH group compared to the non-ICH group. Multivariable Cox regression identified immunocompromised status as an independent risk factor for IPA (adjusted HR, 2.33; 95% CI, 1.07-5.06). Strikingly, immunocompromised hosts (ICHs) accounted for 80.0% of the early-onset IPA cases, compared to only 46.2% in the late-onset group. This association was confirmed in the adjusted analysis, where immunocompromised status remained a powerful independent risk factor for early diagnosis (adjusted OR 35.7, 95% CI 3.71-763.00). Conclusion: Immunocompromised status is an independent risk factor for both the development and earlier onset of IPA in patients with viral pneumonia, underscoring the need for heightened vigilance and early investigation in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.